/ septic shock, surgery, and total parenteral nutrition.8 This Candida Score is expected to help clinicians to start antifungal therapy so there is no excessive use of antifungal therapy associated with increased health costs and the development of resistance from Candida, and the lack of use of antifungal therapy associated with worsening prognosis in critically ill patients. [8] [9] [10] 
Methods
This study is a cross-sectional descriptive study involving critically ill patients who were under treatment in the Intensive Care Unit of Sanglah General Hospital, Denpasar-Bali, Indonesia, from January to June 2019. The sample collection technique used in this study is a total sampling. The patients included in this study were patients who were ≥ 18 years old and under treatment in ICU for at least seven days. Exclusion criteria were as follows: neutropenia defined as a total leukocyte count < 500/mm3, mothers who are breastfeeding or pregnant women, patients who infected with Candida species or currently on antifungal therapy for the first seven days in ICU. This 
Results
Sixty-four patients were included in this study. The most common age group was 60 -69 years and the male-to-female ratio was 1.37:1. Patient characteristics such as age, gender, diagnosis on ICU admission, Apache II Score and ICU length of stay are shown in Table 1 . 
Discussion
Candida Score is a simple scoring system that may help clinicians in differentiating between invasive Candidiasis and Candida species colonization in non-neutropenic critically ill patients. 8, 9 Candida Score can also be used as a reference in starting empirical antifungal therapy.9 Candida Score had a sensitivity of 81% and a specificity of 74% with a cut-off value of 2.5.8
In this study, 16 (25%) patients had a CS value > 2. 5 Empirical antifungal therapy was only given to 11 (68.8%) of 16 patients who had a Candida Score ≥ 2.5, whereas empirical antifungal therapy was not given to all patients with a Candida Score < 2.5. These results are different from the previous study conducted by organs. 11 The doctor must also consider the risks of toxicity, cost-effectiveness, the patient's willingness to be given antifungal therapy, and whether the patient is pregnant or not. 11 Leroy et al., 10 in their study, found that 10 (53%) of 19 patients given empirical antifungal therapy died and 36 (48%) of 75 patients who were not given antifungals died during their ICU stay. They also found that mortality in patients who had CS > 3 and received empirical antifungal therapy was no different from patients who had CS > 3 and did not receive empirical antifungal therapy (6/10 vs. 7/11; p = 1). In this study, empirical antifungal therapy was given to 11 patients and 9 (80.8%) of them died, whereas empirical antifungal therapy was not given to 53 patients and 27 (50.8%) of them died. Echinocandin was a significant predictor of survival. 13 However, this is still the author's opinion so that further research needs to be done related to resistance and susceptible patterns of antifungal agent in the ICU Sanglah General Hospital, Denpasar, Bali, Indonesia.
This study has limitations such as the lack of samples used in this study when compared to the number of samples conducted by Leroy et al. 10 and León et al. 9 . The small number of samples was because this study was only conducted at one tertiary type hospital in Bali, and data were also taken from patients undergoing treatment in the Intensive care Unit from January to June 2019. In addition, prospective research is needed to find out reasons why doctors do not give empirical antifungal therapy to patients who have a Candida Score > 2.5 and the incidence rate of candidiasis in the ICU Sanglah General
Hospital.
Conclusion
The pattern of antifungal administration in critically ill patients with candidiasis in Sanglah General Hospital has relevance to Candida Score. In this study was found that 11 of 16 patients with a CS value > 2.5 were given empirical antifungal therapy, while 48 patients with a CS value of < 2.5 were not given empirical antifungal therapy.
